63rd Annual Meeting of the American Society of Hematology (ASH): New Real-Life Data from DACH Region confirm the Effectiveness and Tolerability of Venetoclax and Rituximab Combination in Patients with r/r CLL

被引：0
|
作者：
不详
机构：
来源：
ACTA HAEMATOLOGICA | 2022年 / 145卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：229 / 229
页数：1
相关论文
共 3 条
  • [1] 63rd Annual Meeting of the American Society of Hematology (ASH): New Real-life Data from the DACH Region confirm the Efficacy and Tolerability of Venetoclax plus Rituximab in r/r CLL
    Krampe-Scheidler, Anne
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 70 - 70
  • [2] Comparison of baseline characteristics of adult CLL patients treated with either Venetoclax monotherapy or Venetoclax in combination with Rituximab under real-life condition - Data from the observational study VeRVe
    Schwaner, I.
    Hebart, H.
    Losem, C.
    Wolff, T.
    Huelsenbeck, J.
    Schmidt, B.
    Rossi, D.
    Noesslinger, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 72 - 73
  • [3] Safety and Effectiveness of Venetoclax/Rituximab in Bcri-Naive and Bcri-Exposed Patients with Relapsed/Refractory CLL Under Real-Life Conditions - Data from the Observational Verve Study
    Rossi, Davide
    Hebart, Holger
    Losem, Christoph
    Wolff, Thomas
    Schmidt, Xenia
    Famulla, Kirsten
    Schmidt, Burkhard
    Noesslinger, Thomas
    Schwaner, Ingo
    BLOOD, 2021, 138 : 3735 - +
1